Claudio Fenizia
Overview
Explore the profile of Claudio Fenizia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vanetti C, Broggiato M, Pezzana S, Clerici M, Fenizia C
Immunol Lett
. 2025 Feb;
272:106976.
PMID: 39900298
Plastics are everywhere. It is widely recognized that they represent a global problem, the extent of which is yet to be defined. Humans are broadly exposed to plastics, whose effects...
2.
Vanetti C, Saulle I, Artusa V, Moscheni C, Cappelletti G, Zecchini S, et al.
Microb Cell
. 2024 Oct;
11:353-367.
PMID: 39421150
Concurrent infections with two or more pathogens with analogous tropism, such as RSV and SARS-CoV-2, may antagonize or facilitate each other, modulating disease outcome. Clinically, discrepancies in the severity of...
3.
Cervia D, Zecchini S, Pincigher L, Roux-Biejat P, Zalambani C, Catalani E, et al.
Free Radic Biol Med
. 2024 Sep;
225:193-207.
PMID: 39326684
Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease. Recently approved molecular/gene treatments do not solve the downstream inflammation-linked pathophysiological issues such that supportive therapies are required to improve therapeutic...
4.
Limanaqi F, Zecchini S, Ogno P, Artusa V, Fenizia C, Saulle I, et al.
Front Cell Dev Biol
. 2024 Jul;
12:1421360.
PMID: 39035028
Abnormal spreading of alpha-synuclein (αS), a hallmark of Parkinson's disease, is known to promote peripheral inflammation, which occurs in part via functional alterations in monocytes/macrophages. However, underlying intracellular mechanisms remain...
5.
Piralla A, Mileto D, Rizzo A, Ferrari G, Giardina F, Gaiarsa S, et al.
Travel Med Infect Dis
. 2024 Mar;
59:102698.
PMID: 38556220
Background: Mpox virus (MPXV) has recently spread outside of sub-Saharan Africa. This large multicentre study was conducted in Lombardy, the most densely populated Italian region accounting for more than 40%...
6.
Vanetti C, Stracuzzi M, Crivellaro E, Ciciliano F, Garziano M, Fenizia C, et al.
Front Immunol
. 2024 Jan;
14:1301766.
PMID: 38250079
Background: Data on the efficacy of three SARS-CoV-2 mRNA BNT162b2 vaccine doses and the role of previous SARS-CoV-2-infection in enhancing vaccine immunogenicity in HIV-vertically-infected people living with HIV (PLWH) are...
7.
Limanaqi F, Zecchini S, Saulle I, Strizzi S, Vanetti C, Garziano M, et al.
Biol Res
. 2024 Jan;
57(1):2.
PMID: 38191441
Background: Increasing evidence suggests a double-faceted role of alpha-synuclein (α-syn) following infection by a variety of viruses, including SARS-CoV-2. Although α-syn accumulation is known to contribute to cell toxicity and...
8.
Perrotta C, Fenizia C, Carnovale C, Pozzi M, Trabattoni D, Cervia D, et al.
Vaccines (Basel)
. 2023 Sep;
11(9).
PMID: 37766157
Messenger RNA (mRNA) vaccines belong to a new class of medications, RNA therapeutics, including both coding and non-coding RNAs. The use of mRNA as a therapy is based on the...
9.
The Immunological Profile of SARS-CoV-2 Infection in Children Is Linked to Clinical Severity and Age
Vanetti C, Lampasona V, Stracuzzi M, Fenizia C, Biasin M, Saulle I, et al.
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047752
Coronavirus disease 19 (COVID-19) is clinically less severe in children, even if the wide variety and degree of severity of symptoms reported in children pose a still-unresolved challenge for clinicians....
10.
Fenizia C, Moltrasio C, Ottobrini L, Utyro O, Genovese G, Vanetti C, et al.
J Invest Dermatol
. 2023 Jan;
143(8):1601-1604.
PMID: 36716924
No abstract available.